Targeting pyroptosis through inhibitors of GSDMD, caspase-1, or the NLRP3 inflammasome represents a promising therapeutic approach for reducing inflammation and improving clinical outcomes in HS patients. This evidence concerns the gene GSDMD and histiocytic sarcoma.